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Bulleted statements:
What’s already known about this topic?


In patients with systemic sclerosis (SSc) many autoantibodies are detected



Some autoantibodies in SSc are likely to be involved in the pathogenesis of the
disease



Studies have reported complement activation in SSc



Studies investigating antibodies against C1q, frequently detected in systemic lupus
erythematosus, have not been performed in SSc

What does this study add?


Anti-C1q antibodies are frequently detected in patients with SSc



Anti-C1q antibody level is the most important risk factor for the presence of lung
fibrosis

Abbreviations: CEN, centromere; CIC, circulating immune complexes; dc, diffuse
cutaneous; lc, limited cutaneous; NC, normal control; RA, rheumatoid arthritis; RNA pol III,
RNA polymerase III; Scl-70, scleroderma 70; SSc, systemic sclerosis; SLE, systemic lupus
erythematosus; SjS, Sjogren’s syndrome;
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Part of this work was presented as a poster, Annual Congress of EULAR, 8-11 June,
London, 2016 (full citation: Liaskos C, Rentouli S, Simopoulou T, et alAB0613 Anti-C1q
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Autoantibodies Are Frequently Detected in Patients with Systemic Sclerosis and Lung
FibrosisAnnals of the Rheumatic Diseases 2016;75 (supp2):1114.

Summary
Background: Anti-C1q autoantibodies (autoAbs) are associated with systemic lupus
erythematosus (SLE) but their presence in other rheumatic diseases has not been
adequately investigated.

Objective: We aim to assessanti-C1q autoAbs and circulating immune complexes (CICs) in
systemic sclerosis (SSc).

Methods: One hundred twenty four patients with SSc (106 females; median age 59.4 years,
range 25-81.4; 75(60.5%) with limited cutaneous SSc[lcSSc], and 49(39.5%) with diffuse
cutaneous SSc[dcSSc]), were studied. Twenty-five patients with Sjögren’s syndrome (SjS),
29 with rheumatoid arthritis (RA), and 38 patients with systemic lupus erythematosus (SLE)
and 53 healthy controls (NC) were also included. ELISAs with high and low salt buffers the
former allowing IgGFc binding to C1q, the latter not allowing IgGFc binding and anti-C1q Ab
binding to C1q were used to measure anti-C1q Abs and CICs.

Results:Anti-C1q Abs were present in20/124 (16.1%) SSc patients [5 had high levels (>80
RU/mL) and 10 patients (50%) had moderate levels (40-80 RU/mL)] compared to 1/25 (4%)
SjS, 1/29 (3.4%) RA patients (p<0.05, for all) and 3/53 (5.7%) NCs (p<0.01). Anti-C1q Abs
were detected in 13/38 (34.2%) SLE patients. Anti-C1q Abs were more frequent in male than
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female SSc patients (p=0.005); this association remaining after multivariate regression
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analysis . Anti-C1q Ab level was the first most important factor in predicting the presence of
pulmonary fibrosis and the second in predicting pulmonary arterial hypertension. Fourteen
SSc patients (11.3%) had CICs.

Conclusions:Anti-C1q autoAbs were frequently detected in patients with SSc and their high
levels predict the co-occurrence of pulmonary fibrosis or pulmonary arterial hypertension.
Introduction
Systemic sclerosis (SSc)is characterized by extensive fibrosis, microvasculopathy including
vasospastic episodes (Raynaud’s phenomenon, RP)and fibrointimal proliferation, and the
presence of many autoantibodies (autoAbs). The pathogenesis of the disease is
incompletely understood 1, 2. Microvasculopathy, as detected by nailfoldcapillaroscopy, and
autoAbsappear years before skin fibrosis. Many autoAbs are detected in SSc, including
disease-specific autoAbs, such as anti-topoisomerase I (anti-Topo I, formerly anti-Scl70) and
anticentromere (anti-CEN)Abs which are independent predictors for the progression of RP to
SSc3-5. Many autoAbs in SSc are likely to be pathogenic, since they promote inflammation
and fibrosis6, 7. These include anti-endothelial cell 8, 9, anti-fibroblast 10, anti-matrix
metalloproteinase-3 11, anti-fibrillin-1 12, anti-angiotensin II type 1 receptor 13, and antiplatelet-derived growth factor receptor antibodies14, 15. The presence of many autoAbsmight
suggest activation of the classical pathway of complement. Indeed, studies in the eighties
reported complement activation in SSc, as suggested by elevated plasma levels of
complement fragment C3d and C4d16. Activated complement (C5b-9)and complement
receptor for C5a (C5aR) were detected in the microvasculature of skin biopsies from patients
with SSc17.Also, reduced function of complement(C1,C4,C3) was detected in SSc18, and
reduced serum levels of C3 and/or C4 was detected in 14% of patients with SSc and were
associated with vasculitis and myositis19.

This article is protected by copyright. All rights reserved.

Anti-C1q autoAbsare frequently detected in systemic lupus erythematosus (SLE) and are
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strongly associated with lupus nephritis20-24. Two SLE studies with small numbers of SSc
patients used as disease controls showed either a small frequency and increase20or no
increased frequency25 of anti-C1q autoAbs in SSc. It should be mentioned that the
methodology of anti-C1q Ab detection faces a technical problem to distinguish between
IgGFc (of immune complexes) binding to C1q and anti-C1 Ab binding to C1q. To clarify
these observations and issues,we assessed the clinical significance of anti-C1q autoAbs in a
large cohort of SSc patients.

Material and Methods
Patients and Controls
One hundred and twenty four patients with SSc (106 females; median age 59.4 years, range
25-81.4; 75 (60.5%) with limited cutaneous SSc[lcSSc], and 49 (39.5%) with diffuse
cutaneous SSc[dcSSc]), were studied. All patients fulfilled the American College of
Rheumatology criteria for SSc, and attended the Out-patient Systemic Sclerosis Clinic of the
Department of Rheumatology and Clinical Immunology, at the University General Hospital of
Larissa, in central Greece4, 26, 27. Demographic, laboratory and clinical data were collected
for all patients (Table 1). Pulmonary arterial hypertension (PAH)was confirmed by right heart
catheterization (RHC) and pulmonary fibrosis was diagnosed with high resolution CTscan.
Conventional treatment regimens included low-dose steroids (<7.5 mg/day) plus
azathioprine or methotrexate. All SSc patients had anti-nuclear antibodies by indirect
immunofluorescence. Twenty five patients with Sjögren’s syndrome (SjS), 29 with
rheumatoid arthritis (RA), and 38 patients with systemic lupus erythematosus (SLE) served
as disease controls, and 53healthy individualsused as normal controls (NCs). A written
informed consent was obtained by all patients and NCs.

This article is protected by copyright. All rights reserved.

The protocol was approved by the Local Ethical Committee of the University General
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Hospital of Larissa, University of Thessaly, Larissa, Greece and all procedures were in
accordance with the revised Declaration of Helsinki.

SSc-related AutoAb testing
All SSc sera are tested at diagnosis for ANA by indirect immunofluorescence, and for anticentromere, anti-Topo I and anti-RNA polymerase III (RNA pol III) Abs. To ensure
consistency, aliquots stored at -80 °C were tested at the same time for anti-C1q Abs by an
ELISA and for anti-Topo I, anti-CEN and anti-RNA pol III Abs by an SSc profile line
immunoassay (Euroimmun, Lubeck, Germany)4. This profile testing would enable correlation
analysis between anti-C1q Abs and SSc-specific antibodies and was performed in
51SScpatients.

Anti-C1q Ab testing by ELISA
Anti-C1q antibodies were measured by enzyme-linked immunosorbent assay (ELISA)
(QUANTA Lite® IgG anti-C1q, INOVA Diagnostics, Inc. San Diego, CA, USA). Testing was
performed according to the manufacturer’s instructions. Briefly,serum samples were diluted
1:10 with high ionic strength buffer that does not allow IgGFc (of circulating immune
complexes, CIC) binding to C1q of plates, and 100 μLof diluted serum was incubated for 30
min at 20 °C.Then, microplate wells were washed (x3) and incubated for 30min at 20 °C with
100 μL of horseradish peroxidase-conjugated anti-human IgG. The plates were washed (x3)
and incubated for 30 min in the dark with 3,3’,5,5’tetramethylbenzidine (TMB) chromogen.
The reaction was terminatedwith stop solution (0.344M sulfuric acid) after 15 minutes. The
absorbance of the samples was read using a microplate reader (BIOTEK, Winnoski, VT,
USA) at a wavelength of 450 nm/620 nm.Tests with >20 Relative Units (RU/mL)were
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considered positive; 20-40 RU weakly positive; 40-80 RU moderately positive; and >80 RU
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strongly positive, according to the manufacturer's interpretation of results.

Measurement of circulating immune complexes (CICs) by ELISA
A second ELISAwas used to measure circulating immune complexes (CICs). Microwell
plates pre-coated with purified human C1q(as above) were used (Inova). This ELISA with
low salt concentration permits IgGFc (of CICs) binding, as well as anti-C1q Ab binding to
C1q of the microplates. CIC-positivity was defined by subtracting high-salt ELISA serum
sample positivity from low-salt ELISA positivity.

Corresponding data were presented in the form of scatter plots or Ab reactivity in patients
and controls and VENN diagram, a set of circles each representing the total number of
patients positive for an autoantibody, to illustrate the relationship between anti-C1q Abs and
the three major SSc-related autoAbs tested for diagnostic purposes (anti-CEN, anti-Scl-70
and anti-RNA III pol autoAb)

Statistical analysis
The required sample size was estimatedusing the statistical software G-power for ANCOVA
(Fixed effects, main effects and Interactions). Parametric and non-parametric tests were
used for our study sample description, as appropriate. Univariate and multivariate regression
analysis was used to study the effect of a battery of parameters on the levels of anti-C1q IgG
levels.In anticipation for clinical and statistical interactions among the variables under study,
the multivariate model was reduced to the most logically robust. To determine whether the
manufacturer’s cut off for anti-C1q antibody levels could be used, we also assessed the cutoff for the anti-C1q IgG assay by plotting a receiver operator characteristic (ROC) curve
using the test results of the patients with SSc versus normal or disease controls. A 95% CI
has been calculated for the AUC. Finally, we used the GINI index from random forest
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analysis to predict the importance of anti-C1q Abs among a bundle of variables in predicting
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pulmonary fibrosis and pulmonary arterial hypertension. Random forest analyses were
implemented using the “randomForest” package with R. P-values smaller than or equal to
0.05 were considered significant. The statistical calculations were performed with Graph
PadPrism Software 5 and R.

Results
Anti-C1q Ab testing
We performed a sample size estimation using G-power analysis for the multivariate model.
Our study required 122 patients (a error probability: 0.05, power;1-β error probability:0.8 and
degrees of freedom:3) (supplementary data). To this end, we obtained serum samples from
124 patients with SSc enrolled in our study. To assess whether the cut off value of 20
RU/mL set by the manufacturer applies to our SSc cohort, we performed ROC curve
analyses (Fig 1). For a specificity (vs NC) set to 1 (95% CI, 0.89 to 1), cut off value had to
be determined at 32.5 RU/mL (sensitivity 0.24, 95% CI, 0.15 to 0.36), while for a predetermined specificity of 0.97 (95% CI, 0.83 to 1, LR, 7.42) the cut off value for anti-C1q
positivity had to be set to 31.3 RU/ml. Taking into account that anti-C1q Ab positivity has
been previously reported to be present in 3-7% of NC, we considered that the desired
specificity had to be set to > 0.93 (Figure 1). According to our ROC analyses a 0.94
specificity (95% CI, 0.79 to 1, LR: 5.02) required a cut off value > 19.45 RU/mL. Thus, we
concluded that the cut off value for anti-C1q Ab, set at 20 RU from the manufacturer, could
also apply to our cohort.
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Overall, anti-C1q Abs were present in 20/124 (16.1%) SSc patients compared to 1/25 (4%)

Accepted Article

SjS patients, 1/29 (3.4%) RA patients (p<0.05, for all) and 3/53 (5.7%) NCs (p<0.01). The
frequency of anti-C1q Abs in patients with SLE was within the reported range (13/38,
34.2%). Amongst the 20 anti-C1q Ab-positive SSc patients, 5 (25%) had high levels (>80
RU/mL), and 10 patients (50%) had moderate levels (40-80 RU/mL).

Figure 3 shows a VENN diagram depicting anti-C1q Ab positivity and the three most specific
SSc autoAbs (Anti-Topo, anti-CEN and anti-RNA pol III). Anti-Topo I, anti-CEN and antiRNA pol III autoAbs did not differ between anti-C1q Ab-positive and anti-C1q Ab-negative
patients (Fig. 3 and Table 1).

Clinical significance of anti-C1q Abs
Anti-C1q Abs were more frequent in male than female SSc patients (7/18, 38.9% vs 13/106,
12.3%, p=0.005) (Table 1 and 2, Supplementary Fig 1). The anti-C1q positivity was also
more frequent in dcSSc than in lcSSc (12/49, 25% vs 8/75, 10.7%, p=0.049). The presence
of anti-C1q Abs was associated with pulmonary fibrosis (p=0.023, Table 1). No other
association was found between the presence of anti-C1q Abs and other clinical features
(digital ulcers, PAH, arthritis, serositis, gastrointestinal involvement, telangiectasia,
scleroderma renal crisis, and calcinosis). However, after performing a multiple regression
analysis, only the effect of the gender persisted (Supplementary Table 2 and Supplementary
Fig 1 and 2). Prediction analysis showed that the Anti-C1q Ab level is the first most
important factor in predicting the presence of pulmonary fibrosis and the second important
factor in predicting pulmonary arterial hypertension (Fig 4).

This article is protected by copyright. All rights reserved.

Prevalence and clinical significance of CICs
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CICsare frequently found in patients with SLE but also in other autoimmune rheumatic
diseases, including RA. CICs were calculated from the low salt buffer ELISA that
allows,apart from anti-C1q Ab binding, IgGFc (of CICs) binding to C1q of the microplate
wells. Overall, 34 (27.4%) SSc patients exhibited positivity with the low salt buffer ELISA,
and therefore, by subtracting 20 patients with anti-C1q Abs, 14 SSc patients(11.3%) were
positive for CICs. No association was found between CICs and demographic, clinical (digital
ulcers, PAH, pulmonary fibrosis, arthritis, serositis, GI involvement, telangiectasias,
scleroderma renal crisis, and calcinosis) or immunological (SSc autoAbs, such as anti-Topo
I, antI-CENP and anti-RNA pol III autoAbs) features (Table 2).

Discussion
The present study found that anti-C1q Abs are frequently detectedin patients with SSc.
There are two reports of anti-C1q Abs testing in SLE, which included patients with SSc. One
SLE study with 55 SSc patients reported a small increase but low frequency of anti-C1q Abs
in SSc compared to NCs (5.5% vs 2.1%) 20 and a second SLE study with 20 SSc patients
reported no difference in the frequency of anti-C1q autoAbs between SSc and NCs (10% vs
10%) 25.The increased prevalence of anti-C1q Abs in our cohort may relate to the enhanced
sensitivity of the assay. As mentioned, the methodology of anti-C1q Ab detection faces a
technical problemto distinguish between IgGFc (of CICs) binding and anti-C1q Ab binding to
C1q of the ELISA plate. This problem has been solved by the use of high salt concentration
in the assay(1 M NaCl) that disrupts the binding of IgGFc to C1q28.

C1q is part of the C1 complex (the other parts being serine proteases C1r and C1s), a
critical component of classical complement pathway of activation. The activation of the
classical complement pathway is initiated by binding of globular head of C1q to Fc region of
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IgG complexed to antigen. Anti-C1q abs bind to collagen-like tail of C1q29.The anti-C1q

Accepted Article

ELISA by INOVA we utilized, has a high ionic strength buffer to disrupt the binding of IgGFc
(of immune complexes) to C1q28, 30 and thus detects only anti-C1q Abs. We also utilized an
ELISA with low ionic strength buffer to detect both anti-C1q Abs plus IgGFc-C1q binding
(circulating immune complexes). By using both assays we could measure anti-C1q Abs as
well as CICs and assess associations of anti-C1q Abs but also associations of CICs.

The diagnostic utility of anti-C1q autoAbs is relatively low since only 5 out of 26 patients
without SSc-specific anti-CEN, anti-Topo I or anti-RNA pol III autoAbs have anti-C1q
autoAbs. Nevertheless, our study shows that serum IgGanti-C1q autoAbs are detected in a
significant percentage of SSc patients; in fact, anti-C1q Abs are equally prevalent with antiRNA pol III Abs, which have so far been considered the third most prevalent autoAb in
patients with SSc. Furthermore, the presence of anti-C1q Abs appears to be more prevalent
in male patients with SSc. The numbers of male patients in this study is small as expected,
since the proportion of male patients in SSc large cohorts and registries is 12%-16%31, 32.
Yet, the association of anti-C1 Abs with male sex stands in multivariate analysis. The
pathophysiological significance of this association is not clear at present. Of relevance, the
prognostic value of anti-C1q levels is highlighted by prediction analysis showing that the antiC1q Ab level is the first most important factor in predicting the co-occurrence of pulmonary
fibrosis and the second important factor in predicting pulmonary arterial hypertension.
Prospective studies must address the significance of this finding, and if such studies are
proved to be correct, the potential of anti-C1q to be used as clinical biomarker must be
studied in greater detail.
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It is logical to assume that alterations of the classical pathway of complement relates to
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microvascular injury. Microvascular damage is an early and critical component of SSc.
Endothelial cell apoptosis in skin biopsies was detected very early in avian scleroderma, and
in the early inflammatory stage of human SSc33, 34 and was caused by anti-endothelial cell
antibodies33, 35. Microvascular clinical manifestations of SSc are serious and include digital
ulcers, resorption of terminal phalanges of digits, PAH, and scleroderma renal crisis. It may
also contribute to organ fibrosis through hypoxia. Male sex is associated with microvascular
features in SSc. For instance, male sex is a risk factor for progression of early PAH in SSc36,
and for early mortality in SSc37, 38 with PAH being the most common cause of death37. Male
sex is also a risk factor for mortality in patients at risk for PAH39. Nevertheless, the relation of
male sex with anti-C1q Abs and PAH should be assessed in larger studies.

However, C1q has other functions independent of complement activation. For instance, C1q
binds to apoptotic cells and increases their clearance by phagocytes (opsonisation)40-42.
Furthermore, it exerts immunosuppressive effects, as C1q-bound apoptotic cells suppressed
dendritic cell- and macrophage-mediated Th1 and Th17 proliferation43. Therefore, the
presence of anti-C1q autoAbs may be related to autoimmunity44, 45and thus may be involved
in the pathogenesis of SSc. As mentioned, anti-C1q abs bind to collagen-like tail of C1q and
this likely impairs the removal of apoptotic cells29. Indeed, anti-C1q Abs from lupus nephritis
patients bind to C1q on early apoptotic cells and significantly reduce phagocytosis of early
apoptotic cells by macrophages45. This suggests that a defective clearance of apoptotic cells
may serve as a source of autoantigens in SSc. Anti-C1q autoAbs from lupus nephritis
patients also inhibit the deposition of C3c on immune complexes(IC)-C1q(opsonisation of
ICs) and the binding of opsonized ICs to red blood cells45, thus suggesting another source of
persisted autoantigens in SSc.Of relevance, we assessed the presence of CICs in our SSc
cohort, and 14 SSc patients (11.3%) tested positive for CICs.Another means by which antiC1q autoAbs are involved in autoimmune disease is through neutrophil extracellular
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traps(NETs). NETs, formed by neutrophils on exposure to pathogens, contain nuclear
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chromatin and granule enzymes, to fight pathogens but may also serve as a source of
autoantigens and promote autoimmunity. C1q binds to NETs(NET opsonisation) thus
facilitating their clearance46. Abs binding to NETs from sera of SLE patients inhibit NETs
degradation and this impairment correlates with lupus nephritis47. However, it is not known if
NET formation is increased in SSc.

In summary, our study found increased frequency of anti-C1q autoAbs and CICs (both
products of plasma cells) in patients with SSc and particularly in male patients. The
presence of increased levels of anti-C1q Abs is a predictive factor for the presence of lung
fibrosis and pulmonary arterial hypertension. Their involvement in the pathogenesis of SSc
needs further assessments.48-51However, their clinical significance needs to be further
assessed in multicentre studies with well-defined SSc patients.
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Figure 1.ROC for anti-C1q antibodies in SSc patients versus normal controls or SSc
patients versus pathological controls

Figure 2. Vertical Scatter plot illustration of anti-C1q antibody responses expressed as
Relative units (RU) in patients with SSc (n=124), Sjögren’s syndrome (n=25), rheumatoid
arthritis (n=29), systemic lupus erythematosus (n=39) and in 53 normal controls (NC). Solid
lines in each group express mean RU±SEM. Tests were considered positive when values
were >20 Relative Units (RU); weak positive in between 20-40 RU; moderately positive in
between 40-80 RU; and strongly positive >80 RU, according to the manufacturer's
interpretation of results.

Figure 3.VENN diagram showing concurrent IgG anti-C1q, anti-CEN, anti-Scl-70 and antiRNA III pol autoantibody reactivities in 51 patients with SSc patients.

Figure 4. Figure. Random forest variable importance plot highlighting the role of anti-C1q in
(A) predicting pulmonary fibrosis (PF) and (B) pulmonary arterial hypertension (PAH). As
illustrated anti-C1q iAb level s the first most important factor in predicting the development of
PF and the second (after age) important factor in predicting PAH.

Supplementary Figures
Supplementary Figure 1. The effect of gender in the anti-C1q antibody levels.
Supplementary Figure 2. The effect of disease phenotype extension of the anti-C1q
antibody levels.
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Table 1. Clinical and immunological associations between anti-C1q antibody positive and anti-C1q antibody negative patients
with systemic sclerosis (SSc): Univariate analysis.

Epidemiological
Mean age, years (±SD)
Females, n (%)/Males, n (%)
Type of SSc
Limited/limited cutaneous, n (%)
Diffuse cutaneous, n (%)
Clinical features
Digital Ulcers, n (%)
Pulmonary fibrosis, n (%)
Pulmonary Arterial Hypertension (n,%)
Arthritis (n,%)
Serositis (n,%)
Telangiectasia (n,%)
Calcinosis (n,%)
GI involvement (no, upper, upper and low, n,%)
Renal Crisis
SSc-specific autoAbs*
Anti-centromere, n (%)
Anti-Topo I, n (%)
Anti-RNA III pol, n (%)

Total SSc patients
(n=124)

Anti-C1q (+)SSc(n=20)

Anti-C1q
(-)SSc(n=104)

p value

53.8 (23)
106 (85.5%)/18(14.5%)

54.5.8 (24.3)
13(65)/7 (35%)

43.3.8 (30.2)
44 (89.4%)/11 (10.6%)

ns
0.005

75 (60.5)
49 (39.5)

8 (40)
12 (60)

67 (64.4%)
37 (35.6%)

0.039

52 (41.9)
41 (33.1)
19(15.3)
23 (18.5)
8 (6.5)
68 (54.8)
17 (13.7)
49 (40.3)/ 69 (55.6)/
5(4)
2 (1.6)

10 (50)
11 (55)
4 (20)
5 (25)
1 (5)
12 (60)
2 (10)
1 (5)/7(35)/12(60)

42 (40.4)
30 (28.8)
15(14.4)
18(17.3)
7 (6.7)
56 (53.8)
15 (14.4)
4 (3.9)/62 (59.6)/38 (36.5)

0.425
0.023
0.508
0.455
0.766
0.643
0.588
0.112

0 (0)

2 (1.9)

>0.99

35 (28.2)
53 (42.7)
18 (14.5)

7(35)
8 (40)
1 (5)

28(26.9)
45 (43.3)
17 (16.3)

0.478
0.760
0.301

This article is protected by copyright. All rights reserved.

ccepted Articl

Table 2.Clinical and immunological associations between CIC-C1q positive and CIC-C1q negative patients with systemic sclerosis (SSc).

Epidemiological
Mean age, years (±SD)
Females, n (%)/Males, n (%)
Type of SSc
Limited/limited cutaneous, n (%)
Diffuse cutaneous, n (%)
Clinical features
Ulcers, n (%)
Pulmonary fibrosis, n (%)
Pulmonary Arterial Hypertension (n,%)
Arthritis (n,%)
Serositis (n,%)
Telangiectasia (n,%)
Calcinosis (n,%)
GI involvement (no, upper, upper and low, n,%)
SSc-specific autoAbs*
Anti-centromere, n (%)
Anti-Topo I, n (%)
Anti-RNA III pol, n (%)

Total SSc patients (n=124)

CIC-C1q (+)SSc(n=34)

CIC-C1q (-)SSc(n=90)

p value

53.8 (23)
106 (85.5%)/18(14.5%)

47.4 (28.3)
25(73.5)/9 (26.5)

54.7 (25.4)
81 (90)/9 (10%)

0.197
0.002

75 (60.5)
49 (39.5)

16(47)
18 (53)

59 (64.5)
31 (35.5)

0.056

52 (41.9)
41 (33.1)
19(15.3)
23 (18.5)
8 (6.5)
68 (54.8)
17 (13.7)
49 (40.3)/ 69 (55.6)/ 5(4)

17 (50)
16 (39)
7 (36.8)
7 (20.6)
1 (2.9)
22 (64.7)
4(11.8)
16(47)/17(50)/1(3)

17 (38.8)
18 (20)
12(13.3)
16 (17.8)
7 (7.8)
46 (51.1)
13 (14.4)
33 (36.7)/52 (57.8)/4 (4.5)

0.263
0.046
0.317
0.782
0.322
0.194
0.683
0.585

35 (28.2)
53 (42.7)
18 (14.5)

11(32.3)
15 (44.1)
2 (5.9)

24(26.7)
38 (42.2)
16 (17.8)

0.554
0.760
0.314
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